(Q46744456)

24 December 2017

title

Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma (English)

1 reference

24 December 2017

1 reference

0 references

Ahmad A Tarhini

1

1 reference

24 December 2017

John M Kirkwood

2

1 reference

24 December 2017

Hussein Tawbi

3

1 reference

24 December 2017

William E Gooding

4

1 reference

24 December 2017

Mohammed F Islam

5

1 reference

24 December 2017

Sanjiv S Agarwala

6

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

24 December 2017

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

24 December 2017

volume

112

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

1131-1138

1 reference

24 December 2017

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Arsenite stabilizes IkappaBalpha and prevents NF-kappaB activation in IL-1 beta-stimulated Caco-2 cells independent of the heat shock response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

A phase II trial of arsenic trioxide in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23284

7 January 2021

Identifiers

DOI

10.1002/CNCR.23284

1 reference

24 December 2017

1 reference

24 December 2017